AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

AbolerIS Pharma Belgium France

to learn more about our transformative approach to immunotherapies.

Company Contact:

Dr. Ann Meulemans, CEO Aboleris
[phone]
[e-mail]

Media & Investor Contact
Amy Conrad
Juniper Point
[e-mail]

Logo - https://mma.prnewswire.com/media/2671455/AbolerIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/aboleris-pharma-announces-first-cohort-dosed-in-phase-1-study-of-abo21009-a-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis-302447861.html